Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
Pharvaris will present eight abstracts at the EAACI Annual Congress 2026 in Istanbul, including one oral presentation and seven posters/flash talks. The key highlight is the oral presentation of end-of-progression results from the Phase 3 RAPIDe-3 trial for deucrictibant immediate-release in hereditary angioedema.
Key figures
- Drug Name
- deucrictibant
- Phase Of Trial
- Phase 3
- Conference
- EAACI Annual Congress 2026
- Trial name
- RAPIDe-3
- Presentation count
- 8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.